2-Arachidonoylglycerol (2-AG)
The brain's principal endocannabinoid and how it differs from THC.
2-AG is not a terpene—it's an endocannabinoid, a lipid signaling molecule made by animal brains, not plants. It matters for cannabis because THC hijacks the same receptors 2-AG normally activates. Supplements or strains claiming to 'boost 2-AG' are marketing fiction; the science of deliberately raising 2-AG in humans is barely past the lab.
What 2-AG is: Classification and Chemistry
2-Arachidonoylglycerol (2-AG) is an endocannabinoid—a lipid signaling molecule synthesized on demand by animal cells—not a terpene Strong evidence[1][2]. Terpenes are volatile hydrocarbons that give plants aroma; 2-AG is a monoacylglycerol, a glycerol backbone esterified to arachidonic acid (a 20-carbon polyunsaturated fatty acid) at the sn-2 position.
2-AG was identified independently in 1995 by research teams in Japan and Israel as an endogenous cannabinoid receptor ligand [1][2]. Along with anandamide (AEA), it is one of the two best-characterized endocannabinoids in mammals Strong evidence[3].
Synthesis and degradation:
- Produced on demand from membrane phospholipids, primarily by the enzymes diacylglycerol lipase alpha and beta (DAGLα, DAGLβ) [4]
- Broken down mainly by monoacylglycerol lipase (MAGL), with smaller contributions from ABHD6 and ABHD12 [4][5]
- Acts as a full agonist at both CB1 and CB2 receptors Strong evidence[3]
- Present in the brain at concentrations roughly 200 times higher than anandamide, making it the principal endogenous CB1 agonist Strong evidence[5]
Unlike THC, which is a partial agonist that persists in the body for hours, 2-AG is synthesized and destroyed rapidly—it functions as a short-range, on-demand neurotransmitter rather than a circulating hormone.
Where 2-AG is Found and How It Functions
2-AG is produced throughout the central and peripheral nervous system and in immune tissues, with the highest concentrations in the brain Strong evidence[3][5]. It functions as a retrograde neurotransmitter: released from postsynaptic neurons, it travels backward across the synapse to activate presynaptic CB1 receptors, thereby dampening further neurotransmitter release Strong evidence[4][5]. This mechanism is critical for synaptic plasticity and neural circuit tuning.
2-AG is also detectable in plasma, breast milk, and various peripheral tissues at lower levels Weak / limited[3]. Trace amounts have been reported in some foods, but dietary 2-AG is not thought to meaningfully contribute to endocannabinoid tone—the molecule is synthesized locally where and when it is needed.
2-AG is not found in the cannabis plant. Cannabis produces phytocannabinoids (THC, CBD, CBG, etc.) and terpenes; 2-AG is exclusively an animal molecule synthesized by mammalian cells.
2-AG and Cannabis: Why the Difference Matters
When you consume THC, it binds the same CB1 receptors that 2-AG normally activates. However, the pharmacological outcomes differ substantially: THC is a partial agonist with a long elimination half-life and distributes systemically across the brain, producing diffuse, prolonged receptor activation Strong evidence[5][6]. By contrast, 2-AG acts locally and transiently. This mismatch provides a mechanistic explanation for both desirable cannabis effects (euphoria, appetite stimulation, analgesia) and unwanted ones (anxiety, memory disruption, tolerance) Strong evidence[5][6].
MAGL inhibitors (drugs that block the enzyme breaking down 2-AG, thereby raising endogenous 2-AG levels) have been studied as a pharmacological alternative to THC. In preclinical rodent models, MAGL inhibition produces analgesic and anti-anxiety effects Strong evidence[7]. However, with chronic dosing, MAGL inhibition also causes CB1 receptor desensitization and tolerance similar to chronic THC exposure, suggesting that simply raising endogenous 2-AG does not fully circumvent the tolerance problem Strong evidence[7].
CBD and the endocannabinoid system: CBD does not directly bind CB1 or CB2 receptors with meaningful affinity. Some evidence suggests CBD can indirectly modulate endocannabinoid tone, including 2-AG and anandamide levels, through effects on degrading enzymes and reuptake mechanisms Weak / limited[3]. This remains an area of active research with limited human data.
What Is Not Yet Known
Endocannabinoid biology in humans remains incompletely mapped. Key open questions include:
- Blood 2-AG as a biomarker: Whether circulating 2-AG levels in blood meaningfully reflect brain endocannabinoid tone is disputed Disputed. Many clinical studies use blood 2-AG as a proxy for central endocannabinoid status, but this assumption lacks solid validation.
- Long-term human neuroadaptation: How chronic cannabis use reshapes the 2-AG / MAGL / CB1 system over months and years, and whether those changes fully reverse after abstinence, is poorly characterized in humans Weak / limited[5].
- Clinical Endocannabinoid Deficiency (CED): The hypothesis that low endocannabinoid tone underlies conditions like migraine, fibromyalgia, and irritable bowel syndrome remains popular but is not yet a formally recognized medical syndrome with reproducible diagnostic criteria Disputed. While some observations support this framework, the evidence base remains limited.
Marketing claims to disregard: If you see a product or influencer claiming to 'boost your 2-AG' through a supplement, exercise regimen, or specific cannabis strain, treat that claim skeptically. The science of deliberately modulating 2-AG in humans is still preclinical or early-clinical for almost every proposed application.
Related Molecules and Further Reading
If you are exploring endocannabinoid biology and cannabis pharmacology, the most relevant related entries are:
- Anandamide (AEA) — the other major endocannabinoid; named from the Sanskrit ananda (bliss).
- Arachidonic acid — the fatty acid building block of both 2-AG and anandamide.
- CB1 receptor and CB2 receptor — the two main targets of endocannabinoids and phytocannabinoids.
- THC — the phytocannabinoid that mimics 2-AG at CB1 receptors but with different kinetics and duration.
- CBD — a phytocannabinoid that interacts with the endocannabinoid system indirectly.
- Exercise-Induced Endocannabinoids — how physical activity affects 2-AG and anandamide.
For an overview of actual cannabis terpenes and their properties, see Beta-Caryophyllene, Limonene, and Myrcene.
Sources
- Peer-reviewed Mechoulam, R., Ben-Shabat, S., Hanus, L., et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology, 50(1), 83–90.
- Peer-reviewed Sugiura, T., Kondo, S., Sukagawa, A., et al. (1995). 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochemical and Biophysical Research Communications, 215(1), 89–97.
- Peer-reviewed Lu, H.-C., & Mackie, K. (2016). An introduction to the endogenous cannabinoid system. Biological Psychiatry, 79(7), 516–525.
- Peer-reviewed Murataeva, N., Straiker, A., & Mackie, K. (2014). Parsing the players: 2-arachidonoylglycerol synthesis and degradation in the CNS. British Journal of Pharmacology, 171(6), 1379–1391.
- Peer-reviewed Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology, 153(2), 199–215.
- Peer-reviewed Schlosburg, J. E., Blankman, J. L., Long, J. Z., et al. (2010). Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nature Neuroscience, 13(9), 1113–1119.
- Peer-reviewed Russo, E. B. (2016). Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis and Cannabinoid Research, 1(1), 154–165.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Beta-Ylangene — A minor sesquiterpene with limited research and no dominant cannabis strains.
- Cannflavin C — A prenylated flavone from cannabis, frequently misclassified as a terpene.
- Caryophyllene — A peppery sesquiterpene that activates CB2 receptors and appears in high concentrations in...
- Exercise-Induced Endocannabinoids — Endogenous cannabinoid signaling during aerobic exercise and the biology of runner's high.
- Limonene — Citrus monoterpene with weak evidence for anxiety relief in cannabis contexts.
- Myrcene — Earthy monoterpene abundant in cannabis, hops, and mango—effects in humans remain unproven...